Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease.
The Phase IIa COURSE trial was a...

Related Keywords

United States ,United Kingdom ,Manchester ,Cambridge ,Cambridgeshire ,Japan ,American ,America ,Brendan Mcevoy ,Sharon Barr ,Dave Singh ,Jillian Gonzales ,American Thoracic Society ,University Of Manchester ,Astrazeneca ,International Conference ,Amgen ,Confidence Interval ,Thoracic Society ,Respiratory Pharmacology ,Executive Vice President ,Respiratory Questionnaire ,Asthma Symptoms ,Obstructive Pulmonary Disease ,Rare Diseases ,News Publishing ,